LFB is committed to Von Willebrand disease at EAHAD 2021
LFB is committed in the therapeutic care of patients suffering from Haemophilia and patients with von Willebrand disease. LFB is participating in the 14th annual congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which will be held virtually from February 3–5, 2021.
LFB’s activities at this Congress include a scientific symposium on Von Willebrand Disease that will be broadcasted online on EAHAD platform on February 5th, 2021, at 18:00 CET.
The LFB symposium will be chaired by Prof. Sophie Susen, Head of the Haematology Department at Lille University Hospital, France, who will also present recently published data in the management of patients with von Willebrand disease in a real-life setting. Prof. Jerzy Windyga, Head of the Department of Disorders of Hemostasis and Internal Medicine at the Institute of Haematology and Transfusion Medicine, Warsaw, Poland, will tackle the evolution of the disease with ageing and particularly the thromboembolic risk in elderly. Prof. Giancarlo Castaman, Director of Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Italy, will address the difficulties in managing gastro-intestinal bleeds in patients with von Willebrand disease.
Besides, 4 scientific abstracts on several LFB studies have been accepted for e-poster presentations during the EAHAD congress: PERSEPT 1 study/on demand treatment of bleeding episodes in adults & adolescents, and PERSEPT 3 study/perioperative care in major surgery in patients with haemophilia, and a post-marketing study/prophylaxis for joint and gastrointestinal bleeding in patients suffering from Von Willebrand disease.